

**ANNOUNCEMENT**

The Board of Directors of Malaysian Genomics Resource Centre Berhad (hereinafter referred to as "MGRC" or "the Company") and its subsidiaries ("the Group") hereby announce the following unaudited results for the first quarter ended 30 September 2012.

**A PRESENTATION OF RESULTS**
**I CONDENSED STATEMENT OF COMPREHENSIVE INCOME**

for the financial period ended	1st Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	30.9.2012 (RM'000)	30.9.2011 (RM'000)	30.9.2012 (RM'000)	30.9.2011 (RM'000)
Revenue	58	3,730	58	3,730
Interest income from fixed deposits	82	153	82	153
Marketing and distribution	(157)	(235)	(157)	(235)
Employee benefits and expense	(1,143)	(1,012)	(1,143)	(1,012)
Depreciation and amortisation	(511)	(452)	(511)	(452)
Lab consumables	(117)	(273)	(117)	(273)
Research collaboration costs	-	(500)	-	(500)
Exclusive license fee	(62)	(62)	(62)	(62)
System maintenance cost	(301)	(301)	(301)	(301)
Administrative expenses	(610)	(567)	(610)	(567)
Foreign exchange gain / (loss)	-	(5)	-	(5)
<b>Profit / (loss) from operations</b>	<b>(2,761)</b>	<b>476</b>	<b>(2,761)</b>	<b>476</b>
Finance costs	-	-	-	-
<b>Profit / (loss) before tax</b>	<b>(2,761)</b>	<b>476</b>	<b>(2,761)</b>	<b>476</b>
Income tax expenses	(21)	(38)	(21)	(38)
<b>Profit / (loss), net of tax, representing total comprehensive income</b>	<b>(2,782)</b>	<b>438</b>	<b>(2,782)</b>	<b>438</b>
<b>Profit / (loss) attributable to:</b>				
Shareholders of the Company	(2,782)	438	(2,782)	438
Minority interest	-	-	-	-
<b>Net profit / (loss) for the period</b>	<b>(2,782)</b>	<b>438</b>	<b>(2,782)</b>	<b>438</b>
<b>Earnings / (Loss) per share (EPS) attributable to the equity holders of the Company (sen)</b>				
Basic EPS	(2.96)	0.47	(2.96)	0.47
Diluted EPS	N/A	N/A	N/A	N/A

The unaudited condensed statement of comprehensive income should be read in conjunction with the audited financial statements for the year ended 30 June 2012 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

Note:-

There is no income/expense in relation to other income including investment income, provision for/write-off of receivables, provision for/write-off of inventories, gain/loss on disposal of quoted or unquoted investments or properties, impairment of assets, gain/loss on derivatives, or exceptional items.

**A PRESENTATION OF RESULTS (cont.)**
**II CONDENSED STATEMENT OF FINANCIAL POSITION**

as at	30.9.2012 (RM'000)	30.6.2012 (RM'000)
<b>ASSETS</b>		
<b>NON-CURRENT ASSETS</b>		
Plant and equipment	5,387	5,653
Intangible asset	4,073	4,226
<b>CURRENT ASSETS</b>		
Trade and other receivables	7,173	6,887
Inventories	958	785
Other current assets	450	957
Cash and bank balances	9,774	12,110
<b>TOTAL ASSETS</b>	<b>27,815</b>	<b>30,618</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY ATTRIBUTABLE TO OWNERS OF THE PARENT</b>		
Share capital	9,410	9,410
Share premium	14,755	14,755
Retained earnings	2,069	4,851
<b>TOTAL EQUITY</b>	<b>26,234</b>	<b>29,016</b>
<b>CURRENT LIABILITIES</b>		
Trade and other payables	1,555	1,574
Tax payable	26	28
<b>TOTAL LIABILITIES</b>	<b>1,581</b>	<b>1,602</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>27,815</b>	<b>30,618</b>
Net assets (RM'000)	26,234	29,016
Net assets per share attributable to equity holders of the Company (sen)	27.88	30.84

The unaudited condensed statement of financial position should be read in conjunction with the audited financial statements for the year ended 30 June 2012 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

**A PRESENTATION OF RESULTS (cont.)**
**III CONDENSED STATEMENT OF CHANGES IN EQUITY**

	Equity, Total (RM'000)	← Non-Distributable →		Distributable Retained Earnings (RM'000)
		Share Capital (RM'000)	Share Premium (RM'000)	
<b>for the financial year ended 30 June 2012</b>				
Opening balance at 1 July 2011	32,676	9,410	14,755	8,511
Total comprehensive income / (loss)	(3,660)	-	-	(3,660)
<b>Closing balance at 30 June 2012</b>	<b>29,016</b>	<b>9,410</b>	<b>14,755</b>	<b>4,851</b>
<b>for the financial period ended 30 September 2012</b>				
Opening balance at 1 July 2012	29,016	9,410	14,755	4,851
Total comprehensive income / (loss)	(2,782)	-	-	(2,782)
<b>Closing balance at 30 September 2012</b>	<b>26,234</b>	<b>9,410</b>	<b>14,755</b>	<b>2,069</b>

The unaudited condensed statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 30 June 2012 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

**A PRESENTATION OF RESULTS (cont.)**
**IV CONDENSED STATEMENT OF CASH FLOWS**

for the financial period ended	Year-to-Date	
	Current Year	Previous Year
	30.9.2012	30.9.2011
	(RM'000)	(RM'000)
<b>Cash flows from operating activities</b>		
Profit / (loss) before tax	(2,761)	476
Adjustments for:		
Amortisation of intangible assets	153	153
Depreciation of plant and equipment	358	299
Interest income	(82)	(153)
Operating profit / (loss) before working capital changes	(2,332)	775
(Increase) / decrease in receivables	221	(857)
(Increase) / decrease in inventories	(173)	(596)
(Decrease) / increase in payables	(19)	(2,685)
Cash (used in) / generated from operations	(2,303)	(3,363)
Taxes paid	(23)	(38)
<b>Net cash (used in) / generated from operating activities</b>	<b>(2,326)</b>	<b>(3,401)</b>
<b>Cash flows from investing activities</b>		
Interest received	82	153
Purchase of plant and equipment	(92)	(217)
<b>Net cash (used in) / generated from investing activities</b>	<b>(10)</b>	<b>(64)</b>
Net (decrease) / increase in cash and cash equivalents	(2,336)	(3,465)
Cash and cash equivalents at beginning of the period	12,110	22,369
<b>Cash and cash equivalents at end of period</b>	<b>9,774</b>	<b>18,904</b>

The unaudited condensed statement of cash flows should be read in conjunction with the audited financial statements for the year ended 30 June 2012 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

**UNAUDITED NOTES TO THE INTERIM FINANCIAL STATEMENTS****B Explanatory Notes Pursuant to MFRS 134****i Basis of Preparation & Changes in Accounting Policies**First-Time Adoption of Malaysian Financial Reporting Standards ("MFRS")

These condensed consolidated interim financial statements, for the period ended 30 September 2012, have been prepared in accordance with MFRS 134 Interim Financial Reporting. These condensed consolidated interim financial statements also comply with IAS 34 Interim Financial Reporting issued by the International Accounting Standards Board. For the periods up to and including the year ended 30 June 2012, the Group prepared its financial statements in accordance with applicable Financial Reporting Standards ("FRS").

These condensed consolidated interim financial statements are the Group's first MFRS condensed consolidated interim financial statements for part of the period covered by the Group's first MFRS annual financial statements for the year ending 30 June 2013. MFRS 1 First-Time Adoption of Malaysian Financial Reporting Standards has been applied.

There is no impact of the transition from FRS to MFRS to the financial position, financial performance and cashflow. This report should be read in conjunction with the audited financial statements for the year ended 30 June 2012 and the accompanying explanatory notes. The explanatory notes provide an explanation of events and transactions that are significant for an understanding of the changes in the financial position and performance of the Group since the year ended 30 June 2012.

Significant Accounting Policies and Applications

The audited financial statements of the Group for the year ended 30 June 2012 were prepared in accordance with FRS. Except for certain differences, the requirements under FRS and MFRS are similar. The significant accounting policies adopted in preparing this condensed consolidated interim financial statements are consistent with those of the audited financial statements for the year ended 30 June 2012.

**ii Auditors' Report on Preceding Annual Financial Statements**

The audited financial statements for the year ended 30 June 2012 were not qualified.

**iii Seasonal and Cyclical Factors**

The operations of MGRC were not significantly affected by seasonal and cyclical factors.

**iv Material and Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow**

There were no material and unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period.

**v Material Changes in Estimates**

There were no material changes in the estimates that had effect(s) on the financial period.

**vi Debt and Equity Securities**

There were no issues, repurchases and repayments of debt and equity securities for the financial period to date.

**vii Dividends Paid**

There were no dividends paid for the financial period.

**viii Segmental Information**

FRS 8 requires identification of reporting segment on the basis of internal reports that are regularly reviewed by the entity's Chief Operating Decision Maker in order to allocate resources to the segment and assess its performance. The management monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. Accordingly, the Group has only one reportable segment for the period under review as well as the foreseeable future. Please refer to the financial statements presented in Part A of this announcement.

**MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD**

(Company No. 652790-V)

(Incorporated in Malaysia under the Companies Act, 1965)

**B Explanatory Notes Pursuant to MFRS 134 (cont.)**
**ix Valuation of Plant and Equipment**

There has been no valuation made on any of the Group's plant and equipment during the current financial period under review.

**x Subsequent Events**

There were no material events subsequent to the end of the current financial period under review that have not been reflected.

**xi Changes in the Composition of the Group**

There were no changes in the composition of the Group, including business combinations, acquisition or disposal of subsidiaries and long-term investments, restructuring and discontinuing operations for the financial period to date.

**xii Contingent Liabilities or Contingent Assets**

There was no contingent liability or contingent asset arising since the last audited annual balance sheet date as at 30 June 2012.

**xiii Capital Commitments**

There were no material capital commitments for the purchase of property, plant and equipment that were not provided for in the interim financial statements as at the end of the financial period.

**xiv Related Party Transactions**

Save as disclosed below, there were no significant related party transactions during the financial period to date:-

**a) Significant Related Party Transactions**

for the financial period ended		1st Quarter		Year-to-Date	
		Current Year	Previous Year	Current Year	Previous Year
Related Party	Nature of Transaction	30.9.2012	30.9.2011	30.9.2012	30.9.2011
		(RM'000)	(RM'000)	(RM'000)	(RM'000)
Neuramatix, our ultimate holding company.	Management fee payable to Neuramatix pursuant to Shared Services Agreement.	195	233	195	233
Synamatix, our holding company.	Exclusive licence fees payable to Synamatix with respect of software developed by Synamatix pursuant to Software License Agreement.	62	62	62	62
Synamatix, our holding company.	System maintenance fees payable to Synamatix for annual maintenance of software licensed by MGRC pursuant to Software License Agreement.	301	301	301	301
		<b>558</b>	<b>596</b>	<b>558</b>	<b>596</b>

**b) Compensation of Key Management Personnel (excluding directors)**

	1st Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	30.9.2012	30.9.2011	30.9.2012	30.9.2011
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Salaries, allowances and bonuses	379	326	379	326
Contributions to defined contribution plan	22	14	22	14
<b>Total short-term employee benefits</b>	<b>401</b>	<b>340</b>	<b>401</b>	<b>340</b>

**B Explanatory Notes Pursuant to MFRS 134 (cont.)**

**xv Cash and Cash Equivalents**

as at	<u>Current Year</u>	<u>Previous Year</u>
	30.9.2012	30.9.2011
	<u>(RM'000)</u>	<u>(RM'000)</u>
Cash on hand and at banks	148	104
Deposits with licensed banks	9,626	18,800
	<u>9,774</u>	<u>18,904</u>

**xvi Inventories**

There was no write-down of inventories during the financial period to date.

**C Explanatory Notes Pursuant to Appendix 9B, ACE Market Listing Requirements**

These condensed consolidated interim financial statements, for the period ended 30 September 2012, have been prepared in accordance with Paragraph 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad.

**i Performance of the Group**
Current Year 1st Quarter versus Previous Year 1st Quarter

For the first quarter ended 30 September 2012, the Group recorded a revenue of RM0.1 million, which represents a reduction of RM3.6 million as compared to a revenue of RM3.7 million for the first quarter in the preceding year.

For the current quarter, the Group recorded a loss before taxation of RM2.8 million as compared to a profit before taxation of RM0.5 million in the same quarter of the preceding year.

The loss before taxation was mainly due to lower revenue (RM0.06 million versus RM3.73 million).

Current Year-to-Date versus Previous Year-to-Date

The Group recorded a revenue of RM0.1 million, which represents a reduction of RM3.6 million as compared to a revenue of RM3.7 million in the previous year-to-date. We continue to see revenue from smaller projects and the decrease was mainly due to the successful completion of our projects with BiotechCorp and the Ministry of Science, Technology and Innovation ("MOSTI").

The Group registered a loss before taxation of RM2.8 million as compared to a profit before taxation of RM0.5 million in the corresponding period of the previous year. The loss before taxation was mainly due to lower revenue (RM0.06 million versus RM3.73 million).

**ii Comparison with Preceding Quarter's Results**

The comparison of this quarter's results with the preceding quarter is set out below.

for the financial period ended	Current Quarter	Preceding Quarter	Variance
	30.9.2012 (RM'000)	30.6.2012 (RM'000)	(RM'000)
Revenue	58	1,068	(1,010)
Profit / (loss) before tax	(2,761)	(1,581)	(1,180)

The variance was attributed to the successful completion of MOSTI projects in the preceding quarter which led to lower revenue being recorded in the current quarter (RM0.06 million versus RM1.07 million). Due to a reduction in bonus provisions, employee benefits expense was lower in the preceding quarter (RM1.14 million versus RM0.82 million).

**iii Prospects of the Group**

MGRC has developed genetic screening products aimed at hospitals, specialist medical centres and consumer market segments under the brand Dtect. There are now six products which screen for the genetic predisposition of non-communicable diseases. New products in the pipeline will also screen for an array of communicable and infectious diseases which will be rolled out on a progressive basis. While R&D efforts continue, management is focused on marketing activities and establishing distribution channels locally and in key international markets.

Once the purchase of Clinipath Group has been completed by MPath, this will represent an established network of around 800 primary care clinics and 8 hospitals/specialist medical centres for the Dtect products serving all major cities in Peninsular and East Malaysia.

Through the efforts of the Group's recently announced subsidiary, MGRCI, interest in our products and services continues to grow internationally. As a result of this, several business and investment opportunities are being pursued.

**iv Variance from Profit Forecast**

The Group did not publish any profit forecast.



**C Explanatory Notes Pursuant to Appendix 9B, ACE Market Listing Requirements (cont.)**
**v Taxation**

MGRC's BioNexus pioneer status accords the Company with tax exemption on its statutory income for qualifying activities. The Group's effective tax rate for the current financial year is thus lower than the Malaysian statutory tax rate of 25%.

Taxation for the financial period ended	1st Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	30.9.2012 (RM'000)	30.9.2011 (RM'000)	30.9.2012 (RM'000)	30.9.2011 (RM'000)
Malaysian income tax:				
Current period	21	38	21	38
Prior period	-	-	-	-
<b>Total</b>	<b>21</b>	<b>38</b>	<b>21</b>	<b>38</b>

The above tax has arisen in relation to interest income.

**vi Status of Corporate Proposal**

The proposed acquisitions set out in the corporate proposal announced to Bursa Malaysia Securities Berhad on 20 July 2012 are progressing and completion is expected to occur within the timeframe stipulated in the relevant agreement.

**vii Status of Utilisation of Proceeds from Issue of Shares**

The Company was listed on the ACE Market of Bursa on 5 October 2010 ("Date of Listing"). The Company raised RM18.5 million from its Initial Public Offering ("IPO") and the details of utilisation of such proceeds as at 30 September 2012 are as follows:

Utilisation of Proceeds Purpose Details (if available)	Initial Timeframe for Utilisation	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated		Explanation
				(RM'000)	(%)	
Capital expenditure	Within two (2) years from the Date of Listing	6,000	5,715	285	5%	
Laboratory equipment		900	900	-	0%	
Computer hardware & software						
R&D expenditure	Within two (2) years from the Date of Listing	1,510	820	690	46%	
Marketing expenditure	Within three (3) years from the Date of Listing	2,000	1,234	766	38%	
Working capital	Within two (2) years from the Date of Listing	4,568	4,880	(312)	0%	#
Listing expenses	Within one (1) month from the Date of Listing	3,490	3,178	312	0%	#
<b>Total utilisation of funds</b>		<b>18,468</b>	<b>16,727</b>	<b>1,741</b>	<b>9%</b>	

# The under utilisation of listing expenses is adjusted to working capital.

**viii Borrowings**

The Group does not have any borrowings as at 30 September 2012.

**ix Material Litigations**

As at the date of this announcement, there are no material litigations against the Group or taken by the Group.

**MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD**

(Company No. 652790-V)

(Incorporated in Malaysia under the Companies Act, 1965)

**C Explanatory Notes Pursuant to Appendix 9B, ACE Market Listing Requirements (cont.)**
**x Dividends**

No dividends were declared during the current financial period under review.

**xi EPS**

- a) **Basic EPS** Computed by dividing the profit / (loss), net of tax, attributable to owners of the parent for the financial period by the weighted average of the number of ordinary shares in issue during the period.

Basic EPS	1st Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
for the financial period ended	30.9.2012	30.9.2011	30.9.2012	30.9.2011
Profit / (loss), net of tax, attributable to owners of the parent (RM'000)	(2,782)	438	(2,782)	438
Weighted average number of ordinary shares of RM0.10 each in issue ('000)	94,100	94,100	94,100	94,100
<b>Basic EPS (sen)</b>	<b>(2.96)</b>	<b>0.47</b>	<b>(2.96)</b>	<b>0.47</b>

- b) **Diluted EPS** The Group does not have any convertible shares or convertible financial instruments for the current financial quarter and financial period to date.

**xii Disclosure of Realised and Unrealised Profits / (Losses)**

as at	30.9.2012 (RM'000)	30.6.2012 (RM'000)
Realised	2,069	4,851
Unrealised	-	-
<b>Retained profit / (loss)</b>	<b>2,069</b>	<b>4,851</b>

**xiii Authorisation for Issue**

The interim financial statements were authorised for issue by the Board of Directors in accordance with a Resolution of the Directors dated 19 November 2012.